Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Zhu D, Xiao S, Yu J, Ai Q, He Y, Cheng C, Zhang Y, Pan Y
Journal
Scientific reports
Year
2017
The early postnatal period is the most dynamic and vulnerable stage in the assembly of intestinal microbiota. Antibiotics are commonly prescribed to newborn preterm babies and are frequently used for a prolonged duration in China. We hypothesized that the prolonged antibiotic therapy would affect the early development of intestinal microbiota and their metabolites. To test this hypothesis, we analyzed the stool microbiota and metabolites in 36 preterm babies with or without antibiotic treatment. These babies were divided into three groups, including two groups treated with the combination of penicillin and moxalactam or piperacillin-tazobactam for 7 days, and the other group was free of antibiotics. Compared to the antibiotic-free group, both antibiotic-treated groups had distinct gut microbial communities and metabolites, including a reduction of bacterial diversity and an enrichment of harmful bacteria such as Streptococcus and Pseudomonas. In addition, there was a significant difference in the composition of gut microbiota and their metabolites between the two antibiotic-treated groups, where the piperacillin-tazobactam treatment group showed an overgrowth of Enterococcus. These findings suggest that prolonged antibiotic therapy affects the early development of gut microbiota in preterm infants, which should be considered when prescribing antibiotics for this population.
Experiment 1
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Antibiotic free group (postnatal day 3)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- combination of penicillin and moxalactam group (postnatal day 3)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- pre-term neonates given a treatment regimen of penicillin (10U kg-1, twice a day) combined with moxalactam (40 mg kg-1, twice a day)
- Group 0 sample size Number of subjects in the control (unexposed) group
- 12
- Group 1 sample size Number of subjects in the case (exposed) group
- 12
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- Matched on Factors on which subjects have been matched on in a case-control study
- birth weight, gestational age, delivery procedure, sex
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
Signature 1
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Source: Text
Description: Composition Analysis of Microbiota
Abundance in Group 1: increased abundance in combination of penicillin and moxalactam group (postnatal day 3)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroides | ||
| Bacteroidota | ||
| Lactobacillus | ||
| Sphingomonas | ||
| Actinomycetota |
Signature 2
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Source: Text
Description: Composition Analysis of Microbiota
Abundance in Group 1: decreased abundance in combination of penicillin and moxalactam group (postnatal day 3)
| NCBI | Quality Control | Links |
|---|---|---|
| Clostridium |
Revision editor(s): WikiWorks
Experiment 2
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- piperacillin-tazobactam group (postnatal day 3)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- pre-term neonates receiving piperacillin-tazobactam (75 mg kg-1, twice a day)
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
Experiment 3
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Antibiotic free group (postnatal day 7)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- combination of penicillin and moxalactam group (postnatal day 7)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- pre-term neonates given a treatment regimen of penicillin (10U kg-1, twice a day) combined with moxalactam (40 mg kg-1, twice a day)
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
Experiment 4
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- piperacillin-tazobactam group (postnatal day 7)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- pre-term neonates receiving piperacillin-tazobactam (75 mg kg-1, twice a day)
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
Signature 1
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Source: Text
Description: Composition Analysis of Microbiota
Abundance in Group 1: increased abundance in piperacillin-tazobactam group (postnatal day 7)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroides | ||
| Enterococcus |
Revision editor(s): WikiWorks
Signature 2
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Source: Text
Description: Composition Analysis of Microbiota
Abundance in Group 1: decreased abundance in piperacillin-tazobactam group (postnatal day 7)
| NCBI | Quality Control | Links |
|---|---|---|
| Klebsiella |
Revision editor(s): WikiWorks
Experiment 5
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- piperacillin-tazobactam group (postnatal day 3)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- combination of penicillin and moxalactam group (postnatal day 3)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- pre-term neonates given a treatment regimen of penicillin (10U kg-1, twice a day) combined with moxalactam (40 mg kg-1, twice a day)
Lab analysis
Statistical Analysis
Alpha Diversity
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Source: Text
Description:
Abundance in Group 1: decreased abundance in combination of penicillin and moxalactam group (postnatal day 3)
| NCBI | Quality Control | Links |
|---|---|---|
| Enterococcus |
Revision editor(s): Chloe
Experiment 6
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- piperacillin-tazobactam group (postnatal day 7)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- combination of penicillin and moxalactam group (postnatal day 7)
Lab analysis
Statistical Analysis
Alpha Diversity
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
Signature 1
Reviewed Marked as Reviewed by Chloe on 2022/03/30
Source: Text
Description:
Abundance in Group 1: decreased abundance in combination of penicillin and moxalactam group (postnatal day 7)
| NCBI | Quality Control | Links |
|---|---|---|
| Clostridium |
Revision editor(s): Chloe
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_336&oldid=82357"
